^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Soft Tissue Sarcoma
    Drug:Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    Excerpt:
    Summary of recommendations...Regorafenib is an option in doxorubicin-pretreated advanced, non-adipogenic STS patients [II, C].
    DOI:
    10.1093/annonc/mdy310
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Soft Tissue Sarcoma: Other Recommended Regimens…Regorafenib